ATYR
aTyr Pharma, Inc.
$0.95
+2.66%
2026-05-08
About aTyr Pharma, Inc.
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Key Fundamentals
Forward P/E
-2.25
EPS (TTM)
$-0.80
ROE
-108.1%
Profit Margin
0.0%
Debt/Equity
17.88
Price/Book
1.31
Beta
0.66
Market Cap
$88.6M
Avg Volume (10D)
1.3M
Recent Breakout Signals
No recent breakout signals detected for ATYR.
Recent Price Range (60 Days)
60D High
$1.11
60D Low
$0.72
Avg Volume
1.2M
Latest Close
$0.95
Get breakout alerts for ATYR
Sign up for Breakout Scanner to receive daily notifications when ATYR triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
aTyr Pharma, Inc. (ATYR) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors ATYR daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. ATYR operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.